<DOC>
	<DOCNO>NCT01770483</DOCNO>
	<brief_summary>The purpose study investigate nitazoxanide use combination interferon alfa ribavirin effective treating Hepatitis c infect type 2 Diabetic patient improve sustained viral response 80 % .Considering study conduct third world country like Pakistan , standard treatment hepatitis C cost effective . The aim introduce new treatment comparable efficacy peginterferon also cost effective .</brief_summary>
	<brief_title>The Role Of Nitazoxanide , Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients</brief_title>
	<detailed_description>After take proper informed consent patient , patient fulfill research criterion randomize 2 group ( control/study ) . Patients group treat conventional interferon alfa Ribavirin.Those study group give tab nitazoxanide 500mg twice daily addition conventional treatment . The patient follow regular interval : 0,4,12,24,48 week.At visit Hepatitis C Virus ( PCR ) RNA , Liver function test , complete blood count do .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<criteria>Hepatitis C genotype 3a Hepatitis C Virus ( PCR ) RNA Detected Alanine transaminase &gt; 60 Diabetic HbA1c &lt; 8 BMI &gt; 23 Previously treat Hepatitis C patient Pregnant female Decompensated liver disease , Child class B OR Thyroid disease , Thyroid stimulate hormone &gt; 10,0.05 Absolute neutrophil count &lt; 1500 , Platelets &lt; 80,000 , Hb &lt; 10g Female , &lt; 11g Male Severe cardiac disease , New York Heart Association2 Moderate severe depression assess Beck Depression Inventory scale</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Nitazoxanide ,</keyword>
	<keyword>Sustained viral response</keyword>
	<keyword>Type 2 DIABETICS</keyword>
</DOC>